# US 2024/0199751 A1 · Methods for treating or preventing asthma by administering an il-4r antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199751 A1
- Document ID: US20240199751A1
- Status: Published application
- Kind: A1
- Application number: 18/495,182
- Filed: 2023-10-26
- Published: 2024-06-20
- Earliest claimed: 2012-08-21
- Assignees: Sanofi Biotechnology; Regeneron Pharmaceuticals, Inc.
- Applicants: Sanofi Biotechnology; Regeneron Pharmaceuticals, Inc.
- Inventors: Marius Ardeleanu; Namita A. Gandhi; Neil Graham; Stephane C. Kirkesseli; Sudeep Kundu; Ross E. Rocklin; Allen Radin; Steven P. Weinstein; Jennifer Davidson Hamilton; Jeffrey Ming
- Web page: https://patentgrep.com/patent/US20240199751A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/247: {IL-4}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/521: Chemokines
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

## Claims

### Claim at position 1

1-131. (canceled)

### Claim 132

A method for reducing the incidence of one or more asthma exacerbations or improving one or more asthma-associated parameters in a subject suffering from eosinophilic asthma comprising administering to the subject a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R), wherein the antibody or antigen-binding fragment comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs: 148, 150, 152, respectively, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs: 156, 158 and 160, respectively.

### Claim 133 (depends on 132)

The method of claim 132, wherein the asthma exacerbation is selected from the group consisting of:
(a) a 30% or greater reduction from baseline in morning peak expiratory flow (PEF) on two consecutive days;
(b) six or more additional reliever puffs of albuterol or levalbuterol in a 24 hour period (compared to baseline) on two consecutive days; and
(c) a deterioration of asthma requiring:
(i) systemic (oral and/or parenteral) steroid treatment, or
(ii) an increase in inhaled corticosteroid to at least 4 times the last dose received prior to discontinuation, or
(iii) hospitalization.

### Claim 134 (depends on 132)

The method of claim 132, wherein the pharmaceutical composition comprises about 75 mg to about 600 mg of the antibody or antigen-binding fragment thereof.

### Claim 135 (depends on 132)

The method of claim 132, wherein the pharmaceutical composition is administered to the subject at a dosing frequency of once a week and/or the pharmaceutical composition administered to the subject systemically, subcutaneously, intravenously or intranasally.

### Claim 136 (depends on 132)

The method of claim 132, wherein the improvement in an asthma-associated parameter is selected from the group consisting of:
(a) an increase from baseline of forced expiratory volume in 1 second (FEV1) of at least 0.10 L;
(b) an increase from baseline of morning peak expiratory flow rate (AM PEF) of at least 10.0 L/min;
(c) an increase from baseline of evening peak expiratory flow rate (PM PEF) of at least 1.0 L/min;
(d) a decrease from baseline of daily albuterol/levalbuterol use of at least 1 inhalation/day;
(e) a decrease from baseline of five-item Asthma Control Questionnaire (ACQ5) score of at least 0.5 points;
(f) a decrease from baseline of nighttime awakenings (no. of times per night) measured daily of at least 0.2 times per night; and
(g) a decrease from baseline of 22-item Sino-Nasal Outcome Test (SNOT-22) score of at least 5 points.

### Claim 137 (depends on 132)

The method of claim 132, wherein a second therapeutic agent is administered to the subject before, after, or concurrent with the pharmaceutical composition.

### Claim 138 (depends on 137)

The method of claim 137, wherein the second therapeutic agent is selected from the group consisting of: a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a leukotriene inhibitor, a corticosteroid, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, a long-acting beta2 agonist and an anti-fungal agent or any combinations thereof.

### Claim 139 (depends on 132)

The method of claim 132, wherein the subject has an elevated level of a biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), IgE, eotaxin-3, periostin, carcinoembryonic antigen (CEA), YKL-40, and fractional exhaled nitric oxide (FeNO).

### Claim 140 (depends on 132)

The method of claim 132, wherein the subject exhibits a blood eosinophil level of at least 300 cells per microliter and/or a sputum eosinophil level of at least 3%.

### Claim 141 (depends on 132)

The method of claim 132, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 162 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 164.

### Claim 142 (depends on 132)

The method of claim 132, wherein the antibody that specifically binds to IL-4R is dupilumb.

### Claim 143

A method of reducing or eliminating an eosinophilic asthma patient's dependence on inhaled corticosteroid (ICS) and/or long-acting beta-agonists (LABA) for the treatment of one or more asthma exacerbations comprising:
(a) selecting a patient who has eosinophilic asthma that is partially controlled or uncontrolled with a background asthma therapy comprising an ICS, a LABA, or a combination thereof;
(b) administering to the patient a defined dose of an antibody or antigen-binding fragment thereof that specifically binds to interleukin-4-receptor (IL-4R) at a defined frequency for an initial treatment period while maintaining the patient's background asthma therapy for the initial treatment period; and
(c) gradually reducing or eliminating the dosage of ICS and/or LABA administered to the patient over the course of a subsequent treatment period while continuing to administer the antibody or antigen-binding fragment thereof to the patient at the defined frequency and dose used during the initial treatment period.

### Claim 144 (depends on 143)

The method of claim 143, wherein:
the ICS is fluticasone, budesonide, or mometasone;
the LABA is salmeterol or formoterol, and/or wherein the ICS/LABA combination is fluticasone/salmeterol, budesonide/formoterol, or mometasone/formoterol;
the dosage of LABA is eliminated at the end of the initial treatment period; and/or
the dosage of LABA and/or ICS is gradually reduced or eliminated over the course of 2 to 8 weeks;
wherein the antibody or antigen-binding fragment thereof comprises heavy chain and light chain complementarity determining region (CDR) sequences from a heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair of SEQ ID NOs: 162/164, or wherein the antibody or antigen-binding fragment thereof comprises heavy chain complementarity determining region (HCDR) sequences of SEQ ID NOs:148, 150 and 152, and comprises light chain complementarity determining region (LCDR) sequences of SEQ ID NOs:156, 158 and 160.

### Claim 145 (depends on 143)

The method of claim 143, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 162 and an LCVR comprising the amino acid sequence of SEQ ID NO: 164.

### Claim 146 (depends on 143)

The method of claim 143, wherein the antibody that specifically binds to IL-4R is dupilumb.

### Claim 147 (depends on 143)

The method of claim 143, wherein the subject exhibits a blood eosinophil level of at least 300 cells per microliter and/or a sputum eosinophil level of at least 3%.

### Claim 148

A method for the treatment of eosinophilic asthma in a subject whose asthma is inadequately controlled with moderate-to-high dose inhaled corticosteroid (ICS) and a second controller medication, comprising sequentially administering to the subject a single initial dose of a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds an interleukin-4 receptor (IL-4R), and wherein administration of the single initial dose is followed by one or more secondary doses of the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises heavy chain and light chain complementarity determining region (CDR) sequences from a heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair of SEQ ID NOs: 162/164, wherein the pharmaceutical composition is an add-on treatment.

### Claim 149 (depends on 148)

The method of claim 148, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 162 and an LCVR comprising the amino acid sequence of SEQ ID NO: 164.

### Claim 150 (depends on 148)

The method of claim 148, wherein the antibody that specifically binds to IL-4R is dupilumb.

### Claim 151 (depends on 148)

The method of claim 148, wherein:
a systemic corticosteroid is administered to the subject before, after, or concurrent with the pharmaceutical composition;
the initial dose and the secondary doses of the pharmaceutical composition each comprise the same amount of the antibody or antigen-binding fragment;
the initial dose comprises 600 mg of the antibody or antigen-binding fragment and each of the secondary doses comprises 300 mg of the antibody or antigen-binding fragment;
the initial dose and the secondary doses of the pharmaceutical composition are administered every two weeks; or
the initial dose and the secondary doses of the pharmaceutical composition are administered every four weeks.
